clinical trial · NCT06584357
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
GAP Innovations, PBC·—·recruiting·n = 1,200
Mild Cognitive ImpairmentAlzheimer's DiseaseAlzheimer's Disease, Early OnsetMemory LossMemory DisordersMemory ImpairmentBiomarker Data CollectionMK6240
brief summary
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.
started
Sep 26, 2024
primary completion
Jul 1, 2028
completion
Jul 1, 2028
last updated
Apr 15, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol